The ESA scenario gets complex: From biosimilar epoetins to activin traps

Nephrology Dialysis Transplantation

Volumn 30, Issue 4, 2015, Pages 553-559

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

activin; anaemia; biosimilars; chronic kidney disease; erythropoiesis stimulating agents

Indexed keywords

ACTIVIN; AKB 6548; ANTIANEMIC AGENT; ERYTHROPOIETIN MIMETIC PEPTIDE; FG 2216; GSK 1278863; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; SOTATERCEPT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; BIOSIMILAR AGENT; ERYTHROPOIETIN;

ANEMIA; ARTICLE; BONE ATROPHY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACTIVINS; ANEMIA; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; HEMATINICS; HUMANS;

EID: 84926639724     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu089     Document Type: Article

References (51)

1. Doshi S, Krzyzanski W, Yue S et al. Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet 2013; 52: 1063-1083
2. Jelkmann W. Recombinant EPO production-points the nephrologist should know. Nephrol Dial Transplant 2007; 22: 2749-2753
3. World Health Organization. International nonproprietary names (INN) for biological and biotechnological substances. http://www who int/ medicines/services/inn/CompleteBioRevdoc%2008-11-07-2-pdf 2007; INN Working Document: 179
4. Schiestl M, Stangler T, Torella C et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-312
5. Okano M, Sato M, Kaneko E et al. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application. Drug Test Anal 2011; 3: 798-805
6. EMA. Guideline. http://www ema europaeu/docs/en-GB/document-library/Scientific-guideline/2010/04/WC500089474 pdf 2010
7. Jelkmann W. Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant 2009; 24: 1366-1368
8. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009; 16: 117-130
9. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004; 3: 43-47
10. Park SS, Park J, Ko J et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci 2008; 98: 1688-1699
11. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92
12. Weise M, Bielsky MC, De Smet K. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29: 690-693
13. Macdougall IC, Roger SD, De Francisco A et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis stimulating agents: new insights. Kidney Int 2012; 81: 727-732
14. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-421
15. Shoji S, Inaba M, Tomosugi N et al. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013; 90: 237-244
16. Jarsch M, Brandt M, Lanzendörfer Met al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008; 81: 63-69
17. Locatelli F, Mandolfo S, Menegato Adorati M et al. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia. J Nephrol 2013; 26: 1114-1121
18. Bonafont X, Bock A, Carter D et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. Nephrol Dial Transplant Plus 2009; 2: 347-353
19. Ratcliffe PJ. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol 2013; 591: 2027-2042
20. Koivunen P, Hirsila M, Gunzler V et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004; 279: 9899-9904
21. Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-hydroxylases. Curr Med Chem 2007; 14: 1853-1862
22. Nagel S, Talbot NP, Mecinovic J et al. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 2010; 12: 481-501
23. Bernhardt WM, Wiesener MS, Scigalla P et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21: 2151-2156
24. Ganz T. Systemic iron homeostasis. Physiol Rev 2013; 93: 1721-1741
25. Macdougall IC, Rossert J, Casadevall N et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361: 1848-1855
26. Macdougall IC, Provenzano R, Sharma A et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368: 320-332
27. Fishbane S, Schiller B, Locatelli F et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368: 307-319
28. Bouman-Thio E, Franson K, Miller B et al. A Phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008; 48: 1197-1207
29. Sathyanarayana P, Houde E, Marshall D et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009; 113: 4955-4962
30. Marino FE, Risbridger G, Gold E. The therapeutic potential of blocking the activin signalling pathway. Cytokine Growth Factor Rev 2013; 24: 477-484
31. Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 2013; 13: 328-341
32. Yamawaki K, Ueda S, Okada T et al. Adult-specific systemic overexpression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. PLoS One 2013; 8: e78076
33. Souza TA, Chen X, Guo Y et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008; 22: 2689-2702
34. Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010; 12: 586-597
35. Ruckle J, Jacobs M, Kramer W et al. Single-dose, randomized, doubleblind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24: 744-752
36. Fields SZ, Parshad S, Anne M et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013; 22: 87-101
37. Murata M, Eto Y, Shibai H et al. Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain. Proc Natl Acad Sci USA 1988; 85: 2434-2438
38. Yu J, Shao LE, Lemas V et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 1987; 330: 765-767
39. Shao L, Frigon NL, Jr, Young AL et al. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 1992; 79: 773-781
40. Nakamura K, Kosaka M, Mizuguchi T et al. Effect of erythroid differentiation factor on maintenance of human hematopoietic cells in co-cultures with allogenic stromal cells. Biochem Biophys Res Commun 1993; 194: 1103-1110
41. Maguer-Satta V, Bartholin L, Jeanpierre S et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003; 282: 110-120
42. Maguer-Satta V, Rimokh R. FLRG, member of the follistatin family, a new player in hematopoiesis. Mol Cell Endocrinol 2004; 225: 109-118
43. Shimizu T, Kawano Y, Takaue Y et al. Diminished erythropoietin-induced erythroid growth in patients with renal anemia is restored by recombinant human erythroid differentiation factor. Am J Hematol 1994; 47: 178-182
44. Shiozaki M, Sakai R, Tabuchi M et al. In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochem Biophys Res Commun 1989; 165: 1155-1161
45. Iancu-Rubin C, Mosoyan G, Wang J et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 2013; 41: 155-166
46. Finberg KE, Whittlesey RL, Fleming MD et al. Down-regulation of Bmp/ Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010; 115: 3817-3826
47. Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol 2013; 20: 208-214
48. Sun CC, Vaja V, Babitt JL et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392-400
49. Truksa J, Lee P, Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 2009; 113: 688-695
50. Besson-Fournier C, Latour C, Kautz L et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 2012; 120: 431-439
51. Bruno E, Horrigan SK, Van Den BD et al. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998; 91: 1917-1923